Selected region : west
Date: : 24th Mar 2017

Current Studies:

The EPIC Study: Studying genes and lung inflammation to understand individual susceptibility to tobacco smoke. 

Smoking causes inflammation in the lungs and can result in some people developing lung damage that becomes a condition called Chronic Obstructive Pulmonary Disease (COPD). Not all smokers develop COPD and it is not known why some people are more susceptible to the effects of cigarette smoke than others. It is thought that a person's genes, as well as some apects of the way their lungs react to inflammation and cigarette smoke, can determine whether they develop COPD or not.

This study is looking to enrol 100 patients who are current or past smokers who have COPD and 100 patients who are current or past smokers that do not have COPD. Participating in this study involves only one visit to the hospital, which will take no longer than two hours.

If you would like to see whether you may be suitable for this study then please click here.

The GoDARTS Study: Genetics of Diabetes Audit and Research in Tayside and Scotland.

This study wants to understand the role our genes, and other biological markers, play in developing and managing diabetes. By conducting this research it will hopefully provide some answers to some of the following questions surrounding the disease; why do some people develop the disease and others don't; why does medication work for some groups of patients with diabetes and not for others and why do some people develop the complications associated with diabetes and others don't.

The other aim of this study is to look at Metformin, which is one of the most commonly used drugs to treat type 2 diabetes. It can also be used in the treatment of type 1 diabetes in conjunction with insulin therapy. Metformin has been on the market for over 60 years yet its mechanism of action is not fully understood. Some patients respond well to the treatment and encounter very little problems, whilst others find it does not work for them and causes many side-effects.

If you would like to find out more about this study then please click here.

The INCOGNITO Trial: Investigating COPD Lung Infections with Different Inhalers. NHS Tayside & NHS Greater Glasgow and Clyde.

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide and a major cause of morbidity in the UK. Patients with COPD are frequently prescribed inhalers which contain steroids or bronchodilators to help reduce symptoms. There are a number of different treatments available for patients with COPD, however some treatments that are of benefit to one group of patients may produce side effects in others.

This trial wants to compare two different inhalers that are both already in use for treating COPD. The researchers believe that the two inhalers will have different effects on the bacteria that live in the lungs and inflammation in the lungs. If this is the case, it means that future treatment could be much more effective as doctors will be able to match the right inhaler to the right patient by measuring their levels of inflammation at the start.

If you would like to read more about this study then please click here.

If you wish to hear more about or participate in health research projects then please join SHARE today.

For more information contact us at SHARE@dundee.ac.uk